Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Slightly Bullish +25

Cardinal Health (CAH) Gains But Lags Market: What You Should Know

📈 Cardinal Health closed at $215.13, rising 1.11% but underperforming the S&P 500's 2.51% gain and Nasdaq's 2.8% increase.

📉 Over the past month, CAH declined by 1.97%, which was smaller than the broader Medical sector drop of 5.12%.

📅 Analysts expect Cardinal Health to report earnings on April 30, 2026, with projected EPS of $2.8 and revenue of $62.42 billion.

📊 Full-year consensus estimates project earnings per share of $10.31 and revenue of $259.27 billion, representing significant year-over-year growth.

🔍 Recent analyst estimate revisions are positively correlated with share price momentum and indicate sentiment toward the company's operations.

💰 Cardinal Health currently trades at a Forward P/E ratio of 20.63, which is premium compared to the industry average of 15.09.

📈 The stock has a PEG ratio of 1.37, lower than the Medical - Dental Supplies industry average of 1.74.

🏆 Cardinal Health holds a Zacks Rank of #2 (Buy), based on its stagnant consensus EPS estimate and positive analyst sentiment.

🎯 The company belongs to the Medical - Dental Supplies industry, which ranks in the top 31% of all industries based on Zacks metrics.

📉 Investors can monitor upcoming earnings releases and estimate revisions for potential near-term share price movements.

🔗 Zacks.com provides a rating model that considers these metrics to help identify stocks with strong performance potential.

📚 The Zacks Rank system has historically shown an average annual return of 25% for #1 stocks since 1988.

Bullish Signals
  • Cardinal Health (CAH) closed at $215.13, marking a +1.11% move from the previous day.
  • Analysts project earnings per share of $2.8 for the upcoming quarter release on April 30, 2026, representing a 19.15% increase year-over-year.
  • Consensus revenue estimates for the upcoming quarter show an escalation to $62.42 billion, which is a 13.74% increase compared to the year-ago quarter.
  • Full-year Zacks Consensus Estimates call for earnings of $10.31 per share and revenue of $259.27 billion, representing year-over-year changes of +25.12% and +16.48%, respectively.
  • Upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
  • Cardinal Health currently carries a Zacks Rank of #2 (Buy), while #1 ranked stocks have generated an average annual return of +25% since 1988.
  • The Medical-Dental Supplies industry ranks in the top 31% of all industries with a current Zacks Industry Rank of 74.
  • Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Risk Factors
  • Cardinal Health (CAH) stock dropped 1.97% in the past month, outperforming the sector's decline but lagging the broader S&P 500's monthly loss of 1.66%. The company is trading at a premium forward P/E ratio of 20.63 compared to its industry average of 15.09.
  • The stock closed at $215.13, posting a +1.11% gain that underperformed the S&P 500's daily gain of 2.51%, the Dow's rise of 2.85%, and the Nasdaq's increase of 2.8%.
  • The company carries a Zacks Rank of #2 (Buy) with stagnant consensus EPS estimates over the past month, which may not reflect immediate near-term share price momentum.
Full Analysis
Cardinal Health (CAH) shares closed the session at $215.13, rising 1.11% despite underperforming the broader market, which saw the S&P 500 gain 2.51%, the Dow rise 2.85%, and the Nasdaq climb 2.8%. Over the past month, CAH stock has declined by 1.97%, a better performance than the Medical sector's 1.97% loss but worse than the S&P 500's slight decline of 1.66%, while trailing the broader index compared to the sector average which dropped 5.12%. Market attention is focused on Cardinal Health's upcoming earnings release scheduled for April 30, 2026. Analysts project quarterly earnings per share (EPS) of $2.8, representing a 19.15% increase year-over-year, with revenue estimates at $62.42 billion, up 13.74% from the same quarter last year. On a full-year basis, Zacks Consensus Estimates forecast earnings of $10.31 per share and revenue of $259.27 billion, projecting year-over-year growth of 25.12% and 16.48%, respectively. The consensus EPS estimate has remained stagnant over the past month, and the stock currently holds a Zacks Rank of #2 (Buy). Valuation metrics indicate Cardinal Health is trading at a Forward P/E ratio of 20.63, which reflects a premium compared to the industry average of 15.09. The PEG ratio stands at 1.37, slightly lower than the Medical - Dental Supplies industry average of 1.74. The industry itself holds a Zacks Industry Rank of 74, placing it within the top 31% of all industries among more than 250 groups. Research suggests that the top half of rated industries historically outperform the bottom half by a factor of 2 to 1, with Cardinal Health currently carrying a buy rating on the Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell).